August 25, 2014 / 9:36 PM / 3 years ago

BUZZ-: Kite Pharma Inc: Lead cancer drug shows promise in trial

** Cancer drug developer’s shares up 31.2 pct at $29.25 in extended trade

** Says its lead drug has potential to treat aggressive form of blood cancer

** The therapy, KTE-C19, involves genetically modifying a patient’s T cells, and is designed to target a protein expressed on the cell surface of some lymphomas and leukemias

** Company says results support investigational new drug application for KTE-C19

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below